Skip to main content
Erschienen in: Clinical and Experimental Medicine 3/2016

14.05.2015 | Original Article

miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor

verfasst von: Xianjuan Shen, Yuehua Guo, Jiajia Yu, Jing Qi, Wei Shi, Xinhua Wu, Hongbing Ni, Shaoqing Ju

Erschienen in: Clinical and Experimental Medicine | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Bone marrow stromal cells (BMSCs) up-regulate B cell-activating factor (BAFF) in multiple myeloma. Increasing experimental evidence has shown that microRNAs play a causal role in hematology tumorigenesis. In this study, we characterized the role of miR-202 in regulating the expression of BAFF in BMSCs. It was found that expressions of BAFF mRNA and protein were increased in BMSCs treated with miR-202 inhibitor. The growth rate of miR-202 mimics transfection cells was significantly lower than that of non-transfected cells. The expression of Bcl-2 protein was down-regulated, and Bax protein was up-regulated after miR-202 mimics transfection. Over-expression of miR-202 in BMSCs rendered MM cells more sensitive to bortezomib. More significantly, the regulatory effect of miR-202 could inhibit the activation of NF-κB pathway in BMSCs. These results suggest that miR-202 functions as a modulator that can negatively regulate BAFF by inhibiting MM cell survival, growth, and adhesion in the bone marrow microenvironment.
Literatur
2.
Zurück zum Zitat Andrews SW, Kabrah S, May JE, et al. Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br J Biomed Sci. 2013;70:110–20.CrossRefPubMed Andrews SW, Kabrah S, May JE, et al. Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br J Biomed Sci. 2013;70:110–20.CrossRefPubMed
4.
Zurück zum Zitat Moreaux Jérôme, Legouffe Eric, Jourdan Eric. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103:3148–57.CrossRefPubMed Moreaux Jérôme, Legouffe Eric, Jourdan Eric. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103:3148–57.CrossRefPubMed
5.
Zurück zum Zitat Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23:10–24.CrossRefPubMed Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23:10–24.CrossRefPubMed
6.
Zurück zum Zitat Fragioudaki M, Boula A, Tsirakis G, et al. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann Hematol. 2012;91:1413–8.CrossRefPubMed Fragioudaki M, Boula A, Tsirakis G, et al. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann Hematol. 2012;91:1413–8.CrossRefPubMed
7.
Zurück zum Zitat Fragioudaki M, Tsirakis G, Pappa CA, et al. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma. Leuk Res. 2012;36:1004–8.CrossRefPubMed Fragioudaki M, Tsirakis G, Pappa CA, et al. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma. Leuk Res. 2012;36:1004–8.CrossRefPubMed
8.
Zurück zum Zitat Shen X, Zhu W, Zhang X, et al. A role of both NF-κB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells. Mol Cell Biochem. 2011;357:21–30.CrossRefPubMed Shen X, Zhu W, Zhang X, et al. A role of both NF-κB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells. Mol Cell Biochem. 2011;357:21–30.CrossRefPubMed
9.
Zurück zum Zitat Xu G, Shen XJ, Pu J, et al. BLyS expression and JNK activation may form a feedback loop to promote survival and proliferation of multiple myeloma cells. Cytokine. 2012;60:505–13.CrossRefPubMed Xu G, Shen XJ, Pu J, et al. BLyS expression and JNK activation may form a feedback loop to promote survival and proliferation of multiple myeloma cells. Cytokine. 2012;60:505–13.CrossRefPubMed
10.
Zurück zum Zitat Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66:6675–82.CrossRefPubMed Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66:6675–82.CrossRefPubMed
11.
Zurück zum Zitat Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114:3625–8.CrossRefPubMedPubMedCentral Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114:3625–8.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord: Drug Targets. 2013;13:16–34.CrossRef Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord: Drug Targets. 2013;13:16–34.CrossRef
13.
14.
Zurück zum Zitat Kong YW, Ferland-McCollough D, Jackson TJ, et al. MicroRNAs in cancer management. Lancet Oncol. 2012;13:e249–58.CrossRefPubMed Kong YW, Ferland-McCollough D, Jackson TJ, et al. MicroRNAs in cancer management. Lancet Oncol. 2012;13:e249–58.CrossRefPubMed
15.
Zurück zum Zitat Corsini LR, Bronte G, Terrasi M, et al. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets. 2012;16(Suppl 2):S103–9.CrossRefPubMed Corsini LR, Bronte G, Terrasi M, et al. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets. 2012;16(Suppl 2):S103–9.CrossRefPubMed
16.
Zurück zum Zitat Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105:12885–90.CrossRefPubMedPubMedCentral Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105:12885–90.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Corthals SL, Sun SM, Kuiper R, et al. MicroRNA signatures characterize multiple myeloma patients. Leukemia. 2011;25:1784–9.CrossRefPubMed Corthals SL, Sun SM, Kuiper R, et al. MicroRNA signatures characterize multiple myeloma patients. Leukemia. 2011;25:1784–9.CrossRefPubMed
18.
Zurück zum Zitat Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011;52:1787–94.CrossRefPubMed Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011;52:1787–94.CrossRefPubMed
19.
Zurück zum Zitat Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74.CrossRefPubMed Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74.CrossRefPubMed
20.
Zurück zum Zitat Chi J, Ballabio E, Chen XH, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct. 2011;6:23.CrossRefPubMedPubMedCentral Chi J, Ballabio E, Chen XH, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct. 2011;6:23.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011;52:1787–94.CrossRefPubMed Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011;52:1787–94.CrossRefPubMed
22.
Zurück zum Zitat Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950–61.CrossRefPubMed Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950–61.CrossRefPubMed
23.
Zurück zum Zitat Schrauder MG, Strick R, Schulz-Wendtland R, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS ONE. 2012;7:e29770.CrossRefPubMedPubMedCentral Schrauder MG, Strick R, Schulz-Wendtland R, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS ONE. 2012;7:e29770.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Nymark P, Guled M, Borze I, et al. Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos-and histology-related changes in lung cancer. Genes Chromosomes Cancer. 2011;50:585–97.CrossRefPubMed Nymark P, Guled M, Borze I, et al. Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos-and histology-related changes in lung cancer. Genes Chromosomes Cancer. 2011;50:585–97.CrossRefPubMed
25.
Zurück zum Zitat Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105:1383–95.CrossRefPubMed Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105:1383–95.CrossRefPubMed
26.
Zurück zum Zitat Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2004;7:585–98.CrossRef Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2004;7:585–98.CrossRef
27.
Zurück zum Zitat Li ZW, Chen H, Campbell RA, et al. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol. 2008;15:391–9.CrossRefPubMed Li ZW, Chen H, Campbell RA, et al. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol. 2008;15:391–9.CrossRefPubMed
Metadaten
Titel
miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor
verfasst von
Xianjuan Shen
Yuehua Guo
Jiajia Yu
Jing Qi
Wei Shi
Xinhua Wu
Hongbing Ni
Shaoqing Ju
Publikationsdatum
14.05.2015
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 3/2016
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-015-0355-4

Weitere Artikel der Ausgabe 3/2016

Clinical and Experimental Medicine 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.